We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

PDS Biotechnology Corporation (PDSB) USD0.00033

Sell:$3.84 Buy:$3.85 Change: $0.1 (2.67%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.1 (2.67%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.1 (2.67%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is engaged in the developing a pipeline of molecularly targeted immunotherapies. The Company owns the T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Its immuno-oncology product candidates are of potential interest for use as a component of combination product candidates to provide treatments across a range of advanced and/or refractory cancers. It develops targeted product candidates to treat several cancers, including Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Its infectious disease candidates are of potential interest as vaccines to prevent COVID-19 and universal influenza.

Contact details

25B Vreeland Road, Suite 300
United States
+ ()

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$106.69 million
Shares in issue:
28.45 million
United States
US dollar

Key personnel

  • Frank Bedu-Addo
    President, Chief Executive Officer, Director
  • Matthew Hill
    Chief Financial Officer and Principal Financial and Accounting Officer
  • Spencer Brown
    Senior Vice President, General Counsel
  • Sanjay Zaveri
    Senior Vice President - Business Development
  • Gregory Conn
    Chief Scientific Officer
  • Lauren Wood
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.